| abstract |
The present invention provides a mutant human DNA polymerase epsilon comprising one or more amino acid residue mutations, wherein the amino acid residue mutation includes a leucine residue at position 952 of the amino acid sequence of the human DNA polymerase epsilon to change to another amino acid residue base mutation. Using the method, novel biomarkers capable of discriminating high-frequency mutant cancers can be provided. |